Non-Small Cell Lung Cancer
Conditions
Keywords
cc-5013, Non Small Cell Lung Cancer, revlimid, celgene, cc5013
Brief summary
Study will deteremine the MTD and evaluate the safety profile of oral lenalidomide on days 1-14 when combined with pemetrexed on day 1 of a 21 days cycle. Subjects will continue on study until documention of disease progression.
Interventions
DRUGCC-5013
DRUGpemetrexed
Sponsors
Prologue Research International
Celgene Corporation
Study design
Allocation
NON_RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Subjects must understand and voluntarily sign an informed consent document. 2. Age \>or= 18 years at the time of signing informed consent form. 3. Subjects must be able to adhere to the study visit schedule and other protocol requirements. 4. Histological or cytologic documentation of advanced NSCLC. 5. Radiographic or clinical evidence of measurable advanced NSCLC. Subjects must have measurable disease at least 2 cm in diameter. 6. Subjects must have been treated and progressed following chemotherapy. 7. ECOG performance status of 0 or 1 (Appendix I: ECOG Performance Status Scale). 8. Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy test within 7 days of starting study drug. In addition, sexually active WCBP must agree to use adequate contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) while on study drug.
Exclusion criteria
1. Any of the following laboratory abnormalities: 1. Absolute neutrophil count (ANC) \<1,500 cells/mm3 (1.5 x 109/L) 2. Platelet count \<100,000 cells/mm3 (100 x 109/L) 3. Serum creatinine \>1.5 mg/dL (133 mmol/L) 4. Serum SGOT/AST or SGPT/ALT \>3.0 x upper limit of normal (ULN) 5. Serum total bilirubin \>or = 1.5 mg/dL (26 mmol/L) 2. Any serious medical condition or psychiatric illness that places the subject at an unacceptable risk for study participation or would prevent the subject from signing the informed consent. 3. Prior history of malignancy (except basal cell or squamous cell carcinoma or carcinoma in situ of the breast) unless the subject has been free of disease for \> 1 year. 4. Known brain or leptomeningeal disease (CT scan or MRI of the brain required only in case of clinical suspicion of central nervous system involvement). 5. More than one prior chemotherapy for advanced NSCLC. 6. Concurrent use of any other anti-cancer agents. 7. Any prior use of lenalidomide. 8. Pregnant or lactating females. 9. Prior \> or = to grade 3 rash or any desquamating (blistering) rash while taking thalidomide. 10. Prior \> or = to grade 3 allergic reaction/hypersensitivity to thalidomide. 11. Use of any standard/experimental anti-cancer drug therapy within 28 days of the initiation of study drug therapy. 12. Known Hepatitis C.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the maximum tolerated dose (MTD) and evaluate the safety profile of oral lenalidomide on days 1-14 and pemetrexed on day 1 every 21 days, as combination therapy to subjects with advanced Non-Small Cell Lung Cancer | — |
Secondary
| Measure | Time frame |
|---|---|
| To explore the anit-tumor activity of the combination of lenalidomide and pemetrexed when given to subjects with advanced NSCLC | — |
Countries
United States
Outcome results
None listed